Article
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2023
Glaser Moritz, Rasokat Anna, Prang Darinka, Nogova Lucia, Wömpner Claudia, Schmitz Jaqueline, Bitter Elisabeth, Terjung Inken, Eisert Anna, Fischer Rieke, John Felix, von Levetzow Cornelia, Michels Sebastian, Riedel Richard, Ruge Lea, Scharpenseel Heather, Siebolts Udo, Merkelbach-Bruse Sabine, Buettner Reinhard, Brägelmann Johannes, Wolf Jürgen, Scheffler Matthias
Abstract excerpt
BACKGROUND: ROS1 fusions are well treatable aberrations in NSCLC. Besides solvent-front mutations (SFM) in resistance to targeted therapy, small-scale ROS1 mutations are largely unknown. We exploratively analyzed the clinical and molecular characteristics of small-scale ROS1 mutations in NSCLC patients without activating ROS1 fusions or SFMs. METHODS: Next-generation sequencing was performed on tissue samples...
Topics
Join the communities discussing this publication.